Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,222
in 5 filings, $701K under 10b5-1 plans

Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-02-05 Gibson Christopher Chief Executive Officer Sale 10b5-1 −20,000 $7.68 $154K 1,273,156
2025-02-05 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock 10b5-1 −20,000 5,956,700
2025-02-03 Taylor Ben R Chief Financial Officer Grant or award +35,018 879,228
2025-02-03 Taylor Ben R Chief Financial Officer Grant or award +13,922 893,150
2025-02-03 Taylor Ben R Chief Financial Officer Shares withheld for taxes −6,544 $7.25 $47K 886,606
2025-02-03 Taylor Ben R Chief Financial Officer Grant or award · Stock Option (Right to Buy) +70,037 70,037
2025-02-03 Khan Najat Chief R&D Commercial Officer Grant or award +210,113 707,085
2025-02-03 Khan Najat Chief R&D Commercial Officer Grant or award +8,049 715,134
2025-02-03 Khan Najat Chief R&D Commercial Officer Shares withheld for taxes −2,753 $7.25 $20K 712,381
2025-02-03 Khan Najat Chief R&D Commercial Officer Grant or award · Stock Option (Right to Buy) +420,226 420,226
2025-02-03 Gibson Christopher Chief Executive Officer Grant or award +525,283 1,261,916
2025-02-03 Gibson Christopher Chief Executive Officer Grant or award +16,809 1,278,725
2025-02-03 Gibson Christopher Chief Executive Officer Shares withheld for taxes −5,569 $7.25 $40K 1,273,156
2025-02-03 Gibson Christopher Chief Executive Officer Grant or award · Stock Option (Right to Buy) +1,050,567 1,050,567
2025-01-10 Gibson Christopher Chief Executive Officer Conversion 10b5-1 +20,000 756,633
2025-01-10 Gibson Christopher Chief Executive Officer Sale 10b5-1 −20,000 $7.05 $141K 736,633
2025-01-10 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock 10b5-1 −20,000 5,976,700
2025-01-08 Gibson Christopher Chief Executive Officer Conversion 10b5-1 +20,000 756,633
2025-01-08 Gibson Christopher Chief Executive Officer Sale 10b5-1 −20,000 $7.31 $146K 736,633
2025-01-08 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock 10b5-1 −20,000 5,996,700

Page 11 of 41 · 805 trades